Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up

Author:

Stratigos Alexander J.,Sekulic Aleksandar,Peris Ketty,Bechter Oliver,Prey Sorilla,Lewis Karl D.,Basset-Seguin Nicole,Chang Anne Lynn S.,Dalle Stéphane,Fernández Orland Almudena,Licitra Lisa,Robert Caroline,Ulrich Claas,Hauschild Axel,Migden Michael R.,Dummer Reinhard,Yoo Suk-Young,Okoye Emmanuel,Bassukas Ioannis,Loquai Carmen,De Giorgi Vincenzo,Eroglu Zeynep,Gutzmer Ralf,Ulrich Jens,Puig Susana,Inocencio Timothy J.,Chen Chieh-I,LaFontaine Patrick R.,Seebach Frank,Lowy Israel,Fury Matthew G.

Funder

Regeneron Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Dermatology

Reference4 articles.

1. Management of high-risk and advanced basal cell carcinoma;Puig;Clin Transl Oncol,2015

2. Efficacy and safety of vismodegib in advanced basal-cell carcinoma;Sekulic;N Engl J Med,2012

3. Regeneron Pharmaceuticals, Inc. Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma. 2021. Accessed January 28, 2022. https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma-301319988.html

4. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: results from an open-label, phase 2, single-arm trial;Stratigos;Lancet Oncol,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3